Molecularly Engineered Nanobodies for Tunable Pharmacokinetics and Drug Delivery.
Ontology highlight
ABSTRACT: The use of single-domain antibody fragments, or nanobodies, has gained popularity in recent years as an alternative to traditional monoclonal antibody-based approaches. Relatively little is known, however, about the utility of nanobodies as targeting agents for delivery of therapeutic cargoes, particularly to vascular epitopes or in the setting of acute inflammatory conditions. We used a nanobody (VCAMelid) directed against mouse vascular cell adhesion molecule 1 (VCAM-1) and techniques for site-specific radiolabeling and bioconjugation to measure targeting to sites of constitutive and inducible antigen expression and investigate the impact of various characteristics (affinity, valence, circulation time) on nanobody biodistribution and pharmacokinetics. Engineering of VCAMelid for bivalent
SUBMITTER: Glassman PM
PROVIDER: S-EPMC7413641 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA